Parrish Medical Center Awarded Patient Safety Movement’s First 5-Star Hospital Ranking
The Patient Safety Movement Foundation (PSMF) today awarded Florida-based Parrish Medical Center with the first-ever Patient Safety Five-Star Hospital ranking for implementing all 13 Actionable Patient Safety Solutions (APSS) – evidence-based processes designed to help hospitals eliminate preventable deaths and improve patient care.
This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180110006162/en/
Patient Safety Movement Foundation founder Joe Kiani (second from left) awards Parrish Medical Center Executive Team with the first five-star hospital rating for patient safety at a ceremony on Wednesday. (Photo: Business Wire)
“We know that implementing all APSS, as a part of a comprehensive patient safety program, helps hospitals eliminate preventable deaths. We believe that by ranking the hospitals based on the number of APSS they have implemented is a good way to get to great results. We cannot hope for zero, we must plan for zero; and Parrish is indeed planning for zero,” said Joe Kiani, Founder of the Patient Safety Movement Foundation.
Mr. Kiani continued, “We are incredibly proud of each committed hospital and hope that bold commitments like that of Parrish Medical Center will become the norm. We invite every hospital to implement all APSS to earn our 5-star rating.”
“This accomplishment is a tribute to the incredible vision and commitment our CEO and leadership began fifteen years ago when we committed to our mission of ‘healing experiences for everyone, all the time,’” explained Edwin Loftin, Chief Nursing Officer. “The Patient Safety Movement Foundation’s Actionable Patient Safety Solutions (APSS) aligned well with our vision to heal families and communities. By implementing these APSS as part of our patient safety program, we are able to achieve remarkable sustained results.”
Beginning in 2018, Patient Safety Movement Foundation is offering ranking to all hospitals who voluntarily join the Patient Safety Movement. The ranking is objective, and is based on the number of APSS and other specific processes hospitals implement.
At Parrish Medical Center, they have achieved some of the following remarkable results:
- Zero ventilator-related pneumonia in 12 years
- One catheter-related UTI in 10 years
- One CLABSI in the past 10 years
The PSMF acknowledge and value the other ratings and ranking systems that already exist, such as the ones from CMS and LeapFrog Group, and believe that this tool is an additive approach to provide the public with more information about hospitals that are committed to patient safety.
For more information about the ranking system please visit: https://patientsafetymovement.org/partners/hospital-ranking/.
About The Patient Safety Movement Foundation:
More than 200,000 people die every year in U.S. hospitals and 3 million worldwide in ways that could have been prevented. The Patient Safety Movement Foundation was established through the support of the Masimo Foundation for Ethics, Innovation, and Competition in Healthcare to reduce that number of preventable deaths to 0 by 2020 (0X2020). Improving patient safety will require a collaborative effort from all stakeholders, including patients, healthcare providers, medical technology companies, government, employers, and private payers. The Patient Safety Movement Foundation works with all stakeholders to address the problems with actionable solutions for patient safety. The Foundation also convenes the World Patient Safety, Science and Technology Summit. The Summit brings together some of the world’s best minds for thought-provoking discussions and new ideas to challenge the status quo. By presenting specific, high-impact solutions to meet patient safety challenges, called Actionable Patient Safety Solutions, encouraging medical technology companies to share the data their products are purchased for, and asking hospitals to make commitments to implement Actionable Patient Safety Solutions, the Patient Safety Movement Foundation is working toward zero preventable deaths by 2020. Visit https://patientsafetymovement.org/.
Patient Safety Movement Foundation
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
Beko Becomes the Naming Partner of Fenerbahçe Men's Basketball Team19.12.2018 13:00 | Tiedote
To forge its support to sports and healthy living, Beko is now the naming partner of Fenerbahçe Men's Basketball Team. Beko has been supporting basketball teams in Turkish Basketball League and also sponsored the European Basketball Championship for many years and now it takes on the naming partnership of Fenerbahçe Men's Basketball Team for 2.5 years. This new naming partnership agreement focuses on “Eat Like A Pro” – an initiative launched by Beko to fight childhood obesity. Through this collaboration, Beko plans to expand the scope of the campaign to promote healthy eating habits among children by advertising their hero basketball players as role models. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181219005026/en/ Beko Becomes Naming Partner of Fenerbahce Men’s Basketball Team (Photo: Business Wire) Beko, a leading white goods brand providing products and services in more than 130 countries, returns to investing in bas
Mopria Powers IPP Print Solution in Windows 10 Update19.12.2018 11:00 | Tiedote
The Mopria® Alliance, a global non-profit membership organization providing universal standards and solutions for print and scan, today announced that Microsoft, a member of the Mopria Alliance, has implemented an IPP printing solution based on the Mopria standard, in the latest version of the Windows 10 operating system. Mopria is a set of standards offering simple and seamless printing to millions of certified printers and multi-function printers. Beginning with Windows 10 October 2018 Update, Windows added support for Mopria certified printers. When users install a new printer and Windows Update is not available, Windows will automatically install the Mopria certified printers. This eliminates the need for users to install any additional software or drivers, allowing them to print easily, regardless of the printer’s brand. “Implementing the Mopria standard in the most recent Windows Update enables us to continue to modernize the printing process for our customers,” said David Lemson
Chugai's Satralizumab Receives FDA Breakthrough Therapy Designation for Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorders19.12.2018 11:00 | Tiedote
Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for Chugai’s anti-interleukin-6 (IL-6) receptor humanized recycling antibody satralizumab, an investigational medicine for neuromyelitis optica and neuromyelitis optica spectrum disorders (NMO/NMOSD). “Satralizumab is a recycling antibody created utilizing Chugai’s proprietary antibody engineering technologies. We are delighted by the FDA’s designation for this innovative antibody based on the results of a Chugai-initiated global Phase III study” said Chugai’s Executive Vice President, Co-Head of Project & Lifecycle Management Unit, Dr. Yasushi Ito. “Satralizumab is designed to inhibit signaling of the inflammatory cytokine IL-6, which is known to play a role in the pathogenesis of NMO/NMOSD. We continue our efforts to hopefully bring satralizumab as a new treatment option as soon as possible to people living with this devastating disease
Chugai’s Satralizumab Meets Primary Endpoint in Phase III Monotherapy Study in NMOSD19.12.2018 11:00 | Tiedote
Chugai Pharmaceutical Co., Ltd. (TOKYO:4519) announced that a phase III monotherapy study of satralizumab (development code: SA237), SAkuraStar Study (NCT02073279) for the treatment of neuromyelitis optica spectrum disorder (NMOSD), which currently has no approved treatments, has achieved the primary endpoint. The primary endpoint was time to first protocol-defined relapse in the double-blind period. A statistically significant reduction in the risk of relapse was confirmed in patients who received satralizumab, compared to those who received placebo. Furthermore, the safety profile of satralizumab was consistent with that seen in previous studies. Further details will be presented at a future medical meeting. “We are pleased that satralizumab showed benefits also in a monotherapy setting following the previous results as add-on to baseline treatment in patients with NMOSD,” said Dr. Yasushi Ito, Chugai’s Executive Vice President, Co-Head of Project & Lifecycle Management Unit. “We wil
SES Successfully Placed EUR 400 Million Multi-Tranche Schuldschein Loan19.12.2018 10:50 | Tiedote
SES S.A., the world’s leading satellite operator, has completed the syndication of Schuldschein Loans for a total amount of EUR 400 million, comprising a EUR 150 million 5.5-year floating tranche at Euribor 6 months plus 0.80% and a EUR 250 million 7-year fixed rate tranche with a coupon of 1.71%. SES is rated Baa2/BBB- (both with stable outlook). The Schuldschein loan was upsized from the initially marketed size and was placed with several European and Asian institutions. The proceeds will support SES’ general corporate purposes and the refinancing of existing debt maturities which include a USD 500 million 144A bond with a coupon of 2.5% and a final maturity date of 25 March 2019. Andrew Browne, Chief Financial Officer of SES, commented: “We are pleased to have secured this financing at very attractive terms and expanding our investor base while extending our debt maturity profile, where we now have no further senior debt maturities to be financed until early 2020.” BNP Paribas, ING
Bentall Kennedy and GreenOak Real Estate Announce Merger to Form Bentall GreenOak, Global Real Estate Investment Platform19.12.2018 10:39 | Tiedote
Bentall Kennedy and GreenOak Real Estate (“GreenOak”) announced today the signing of an agreement to merge the two firms into a leading global real estate investment platform. The combined entity will be named Bentall GreenOak. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181218005992/en/ GreenOak Co-Founders, John Carrafiell and Sonny Kalsi, existing GreenOak senior management and GreenOak’s strategic partner Tetragon Financial Group Limited will all continue to hold significant ownership stakes in Bentall GreenOak. Bentall Kennedy’s senior management team will also acquire a meaningful ownership position in the combined firm. Bentall GreenOak will be majority-owned by Sun Life Financial (“Sun Life”) and will operate under Sun Life Investment Management, the alternative asset management arm of Sun Life. Sun Life has committed significant co-investment capital to support the growth of Bentall GreenOak and to enhance the fi
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme